Home>>Signaling Pathways>> Apoptosis>> RIP kinase>>Nec-4
Nec-4 Catalog No.GC33620

Size Price Stock Qty
250mg Please Inquire Please Inquire
500mg Please Inquire Please Inquire

Customer Review

Based on customer reviews.

Tel: (626) 353-8530 Email: sales@glpbio.com

Sample solution is provided at 25 µL, 10mM.

Quality Control

Quality Control & SDS

View current batch:

Chemical Properties

Cas No. 1041644-43-2 SDF Download SDF
Synonyms N/A
Chemical Name N/A
Canonical SMILES C[C@@H](C1=C(C=CC=C1Cl)F)NC(C2=CC=C(N2C)C#N)=O
Formula C15H13ClFN3O M.Wt 305.73
Solubility Soluble in DMSO Storage Store at -20°C
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
Shipping Condition Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
  • Molarity Calculator

  • Dilution Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
**When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / CoA (available online).

Calculate

Background

Nec-4, a tricyclic derivative, is a potent receptor interacting protein 1 (RIP1) inhibitor, with an IC50 of 2.6 μM, Ki of 0.46 μM.

Nec-4 (compound 9) is a slightly better competitor than 7 with a lower Ki value that is similar to R-3. Nec-4 is again a slightly better competitor than Rac-3 with Ki and IC50 values comparable to 7 (Nec-4: IC50=2.6±0.1 μM, Ki=0.46±0.05 μM; 7: IC50=10.7±1.8 μM, Ki=4.5±0.9 μM). Overall, all three compounds cross-compete with each other but Nec-4 is able to more effectively displace both 20 and 26 in comparison to the parent compounds Rac-3 and 7, respectively. This suggests that Nec-4 binding likely significantly overlaps with both the Nec-1 and the Nec-3 binding sites.

[1]. Maki JL, et al. Fluorescence polarization assay for inhibitors of the kinase domain of receptor interacting protein 1. Anal Biochem. 2012 Aug 15;427(2):164-74.